(5S)-(+)5-Methyltetrahydrofurfurylalkohol, Racemat | 1140918-31-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: (5S)-(+)5-Methyltetrahydrofurfurylalkohol, Racemat
• 英文别名: ((5S)-5-methyltetrahydrofuran-2-yl)methanol；[(5S)-5-methyloxolan-2-yl]methanol
• CAS: 1140918-31-5
• 化学式: C₆H₁₂O₂
• 分子量: 116.16
• InChiKey: PCZHHBOJPSQUNS-ZBHICJROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20090105306A1

  公开（公告）日：2009-04-23

  The present invention relates compounds of formula (I) wherein A and R 1 are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.

  本发明涉及以下式（I）的化合物 其中A和R1如规范中所定义，包括这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗疾病和疾病的方法。
• COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20100249129A1

  公开（公告）日：2010-09-30

  Disclosed herein are compounds of formula (I) wherein Ring A and R 1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

  本文揭示了以下式(I)的化合物 其中环A和R 1 如规范中所定义。还披露了包含这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗疾病和疾病的方法。
• Cannabinoid receptor ligands
  申请人：Abbott Laboratories

  公开号：EP2428507A2

  公开（公告）日：2012-03-14

  Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  此处公开的是式 (I) 的大麻素受体配体 其中 A1、A5、Rx、X4 和 z 如说明书中所定义。还公开了包含此类化合物的组合物，以及使用此类化合物和组合物治疗疾病的方法。
• Compounds as cannabinoid receptor ligands
  申请人：Abbvie Inc.

  公开号：EP2851366A1

  公开（公告）日：2015-03-25

  Disclosed herein are compounds of formula (I) wherein Ring A and R1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

  本文公开了式 (I) 的化合物，其中环 A 和 R1 如说明书中所定义。还公开了包含此类化合物的药物组合物，以及使用此类化合物和药物组合物治疗疾病的方法。
• MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3173419A1

  公开（公告）日：2017-05-31

  The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

  本发明提供了修饰的核苷、其类似物以及由其制备的低聚化合物。更具体地说，本发明提供的修饰核苷及其类似物可用于加入低聚化合物的末端。这种低聚化合物也可以包含在双链组合物中。在某些实施方案中，本发明提供的低聚化合物可望与靶 RNA 的一部分杂交，导致靶 RNA 丧失正常功能。